ONO 1714

Drug Profile

ONO 1714

Latest Information Update: 28 Oct 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ono Pharmaceutical
  • Class 2 ring heterocyclic compounds; Amidines; Small molecules
  • Mechanism of Action Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypotension; Shock; Type 1 diabetes mellitus

Most Recent Events

  • 30 Sep 2002 Discontinued - Clinical-Phase-Unknown for Shock in United Kingdom (Injection)
  • 30 Sep 2002 Discontinued - Phase-I for Hypotension in United Kingdom (Injection)
  • 30 Sep 2002 Discontinued - Phase-II for Hypotension in Japan (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top